Maximus
MMS
344 hedge funds and large institutions have $5B invested in Maximus in 2023 Q4 according to their latest regulatory filings, with 63 funds opening new positions, 102 increasing their positions, 128 reducing their positions, and 34 closing their positions.
85% more first-time investments, than exits
New positions opened: 63 | Existing positions closed: 34
12% more capital invested
Capital invested by funds: $4.47B → $5B (+$528M)
7% more funds holding
Funds holding: 322 → 344 (+22)
0.68% less ownership
Funds ownership: 98.43% → 97.75% (-0.68%)
6% less call options, than puts
Call options by funds: $2.86M | Put options by funds: $3.05M
20% less repeat investments, than reductions
Existing positions increased: 102 | Existing positions reduced: 128
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
Top Buyers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$44.3M |
| 2 |
Morgan Stanley
New York
|
+$34.2M |
| 3 |
BlackRock
New York
|
+$30.8M |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
+$29.9M |
| 5 |
Norges Bank
Oslo,
Norway
|
+$16.1M |
Top Sellers
MMS Hedge Fund Activity: Q4 2023 in Review
344 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Maximus (MMS) for Q4 2023, worth a combined $5B — up 12% from $4.47B a quarter earlier.
Buyers outnumbered sellers: 63 funds opened new MMS positions and 34 closed out — a net gain of 29 holders — while 102 added to existing stakes and 128 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $44.3M. The largest seller was Point72 Asset Management, cutting an estimated $37.8M.
- 344 institutional investors held Maximus (MMS) as of Q4 2023, up from 322 in Q3 2023.
- Funds reported $5B of Maximus stock for Q4 2023, up 12% quarter-over-quarter.
- 63 funds opened new Maximus positions in Q4 2023 and 34 closed out, a net change of +29 holders.
- The largest Maximus buyer in Q4 2023 was Fidelity Investments, an estimated $44.3M added.
- The largest Maximus seller in Q4 2023 was Point72 Asset Management, an estimated $37.8M sold.
Based on aggregated 13F filings for Q4 2023.